GlassScriptPhysician profile
Sarah Seelye
NPI 1750780102
$2,162.60
in general payments reported to CMS, 2019-2025
22 companies · $844 in 2025
The $844 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.08 · 2023: $374 · 2024: $926 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,143.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $304.19 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $216.94 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $201.43 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Genzyme Corporation | $184.52 | 2024-2025 | |
| Axonics, INC. | $182.56 | 2024 | Axonics |
| Abbott Laboratories | $179.87 | 2022-2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $177.66 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $103.07 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.81 | 2024-2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $89.32 | 2023 | Quviviq |
| Exact Sciences Corporation | $79.92 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $54.30 | 2024 | |
| Sumitomo Pharma America, INC. | $49.47 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.08 | 2024 | Xifaxan |
| Organon LLC | $38.79 | 2025 | Nexplanon |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $32.79 | 2024-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $32.14 | 2024 | |
| Abbvie INC. | $29.18 | 2025 | |
| Corium, LLC | $21.45 | 2024 | Azstarys |
| Dynavax Technologies Corporation | $17.13 | 2024 | Heplisav-B |
| Axsome Therapeutics, INC. | $15.68 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $6.30 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Seelye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.